{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:04:19Z","timestamp":1784199859279,"version":"3.55.0"},"reference-count":70,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100017964","name":"Tianjin Municipal Health Commission","doi-asserted-by":"publisher","award":["TJWJ2025RC008"],"award-info":[{"award-number":["TJWJ2025RC008"]}],"id":[{"id":"10.13039\/100017964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015406","name":"Tianjin Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["21JCYBJC01060"],"award-info":[{"award-number":["21JCYBJC01060"]}],"id":[{"id":"10.13039\/501100015406","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the concordance and correlation between programmed death\u2010ligand 1 (PD\u2010L1) expression in tumor tissue and circulating tumor cells (CTCs), explore the intrinsic link between epithelial\u2010mesenchymal transition (EMT) and PD\u2010L1 expression in CTCs, and examine the predictive value of FDG metabolic parameters, CTCs and their PD\u2010L1 expression for early tumor response and long\u2010term prognosis in patients with advanced non\u2010small cell lung cancer (NSCLC) receiving immune checkpoint inhibitor (ICI) monotherapy or ICI combined with chemotherapy as first\u2010line treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 42 patients with advanced or metastatic NSCLC who received ICI monotherapy or combination chemotherapy as first\u2010line treatment were enrolled as the study population. Pre\u2010treatment peripheral blood CTCs and PD\u2010L1 expression on CTCs were detected. Furthermore, F\u201018\u2010fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography (18F\u2010FDG PET\/CT) tumor metabolic parameters, including maximum standardized uptake value (SUVmax), standard uptake value of lean body mass (SUL), metabolic tumor volume (MTV), total lesion glycolysis (TLG), whole\u2010body metabolic tumor volume (WMTV), and whole\u2010body total lesion glycolysis (WTLG) were collected and measured. Tumor early response was monitored using response evaluation criteria in solid tumors (RECIST criteria) at 8\u2009weeks after ICI treatment, and the differences in CTC PD\u2010L1 expression, FDG metabolic parameters, and clinical data between early respongders and non\u2010responders were analyzed. Finally, the enrolled patients were followed up to evaluate progression\u2010free survival\/overall survival (PFS\/OS) and its associated predictive factors. Bootstrap internal validation (1000 repeated samples) was used to evaluate the robustness of the above prognostic model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The percentage of PD\u2010L1\u2010positive cells in tumor tissue and CTC represents different immune characteristics of patients, and the correlation between these two percentages was not statistically significant (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.041,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.827). However, an intrinsic connection was identified between the EMT process and PD\u2010L1 expression in CTCs, with PD\u2010L1 expression in CTCs gradually increasing as the EMT process in CTCs changed. Furthermore, tumor proportion score (TPS) demonstrated a significant positive correlation with SUVmax (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.684\uff1b\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and SUL (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.603\uff1b\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), with SUVmax and SUL increasing as TPS increased. Patients who exhibited an early response after 8\u2009weeks of treatment had significantly higher SUVmax and SUL values, but lower mixed CTCs, than those in the non\u2010response group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). The combination of SUVmax and PD\u2010L1+ mixed CTCs yields a sensitivity of 81% and a specificity of 71% for predicting early response to ICI therapy in patients with NSCLC, but the combination did not result in a substantial enhancement in predictive efficacy. PD\u2010L1+ mesenchymal CTCs (HR\u2009=\u20095.520, 95% CI 1.993\u201315.291) and WTLG (HR\u2009=\u20094.315, 95% CI 1.864\u20139.991) were identified as independent predictors of PFS, while PD\u2010L1+ mesenchymal CTCs (HR\u2009=\u20092.880, 95% CI 1.124\u20137.381) were identified as independent predictors of OS. Bootstrap resampling analysis (\n                      <jats:italic>B<\/jats:italic>\n                      \u2009=\u20091000 iterations) revealed that PD\u2010L1+ mesenchymal CTCs and WTLG achieve an apparent area under the ROC curve (AUC) of 0.822 for predicting PFS, with a bootstrap\u2010corrected mean AUC of 0.821 (95% CI: 0.714\u20130.917). For OS prediction, PD\u2010L1+ mesenchymal CTCs yielded an apparent AUC of 0.893 and a bootstrap\u2010validated mean AUC of 0.88 (95% CI: 0.655\u20130.975). Furthermore, the combination of PD\u2010L1+ mesenchymal CTCs and WTLG revealed that patients with WTLG &lt;\u20091627.4 (g) and PD\u2010L1+ mesenchymal CTCs &lt;\u20091\/5\u2009mL exhibited prolonged PFS and OS (median PFS was 12.5\u2009months; median OS was 18.5\u2009months), while those with WTLG \u2265\u20091627.4 (g) and PD\u2010L1+ mesenchymal CTCs \u2265\u20091\/5\u2009mL experienced the shortest PFS and OS (median PFS was 1.35\u2009months; median OS was 3.0\u2009months). Patients with PD\u2010L1+ mesenchymal CTCs \u2265\u20091\/5\u2009mL or WTGL \u2265\u20091627.4 (g) exhibited a PFS and OS that fell between the two groups (median PFS was 6.0\u2009months; median OS was 8.0\u2009months). Stability analysis was conducted on the prognostic model after the combination of PD\u2010L1+\u2009mesenchymal CTCs and WTLG. Bootstrap resampling analysis (\n                      <jats:italic>B<\/jats:italic>\n                      \u2009=\u20091000 iterations) showed that the AUC value of the original ROC curve was 0.821, the mean AUC was 0.823 (95% CI: 0.716\u20130.914) when predicting PFS. For OS prediction, the AUC value of the original ROC curve was 0.875, the mean AUC was 0.874 (95% CI: 0.751\u20130.966).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>EMT is associated with PD\u2010L1 expression in CTCs, with CTCs exhibiting a mesenchymal phenotype tending to have higher PD\u2010L1 expression. PD\u2010L1+ mixed CTCs, SUVmax, and SUL were associated with early response to ICI\u2010based treatment. Preliminarily, PD\u2010L1+ mesenchymal CTCs, as an exploratory biomarker, were significantly associated with PFS and OS and may provide prognostic information complementary to conventional tissue\u2010based PD\u2010L1 assessment and FDG metabolic parameters. However, because PD\u2010L1 expression in primary tumor tissue and CTCs was assessed using different detection methodologies, the observed discordance should be interpreted as potentially reflecting both biological heterogeneity and methodological variation. These findings require further validation in larger cohorts using harmonized detection platforms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.72001","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:10:09Z","timestamp":1781082609000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic and Predict Value of Peripheral Blood Circulating Tumor Cells Programmed Death\u2010Ligand 1 Expression and F\u201018\u2010Fluorodeoxyglucose Metabolic Parameters in Patients With Advanced Non\u2010Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2845-0623","authenticated-orcid":false,"given":"Momo","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine Tianjin First Central Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisikaer","family":"Aikedan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Tianjin First Central Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2772-6138","authenticated-orcid":false,"given":"Zhongying","family":"Rui","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Tianjin First Central Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enci","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Tianjin First Central Hospital  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Tianjin First Central Hospital  Tianjin China"},{"name":"Nankai University  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2015.957187"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5190"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3988-1"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50079-2"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000001025"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10651-5"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04500-7"},{"issue":"9","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/2010924","article-title":"Relationship Between SP142 PD\u2010L1 Expression and 18 F\u2010FDG Uptake in Non\u2010Small\u2010Cell Lung Cancer","volume":"2020","author":"Zhao L.","year":"2020","journal-title":"Contrast Media & Molecular Imaging"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2011.08.020"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.12111148"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2017.11.005"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28404"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.10.15.16585"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.305805.117"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.09.010"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2014.1002731"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0421-2"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12643"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep31726"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.04.001"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060835"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14767"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jimed.2020.07.008"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2024.12583"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544100-00004"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01314-4"},{"issue":"1","key":"e_1_2_11_30_1","first-page":"601","article-title":"Epithelial\u2010Mesenchymal Transition Phenotype of Circulating Tumor Cells Is Associated With Distant Metastasis in Patients With NSCLC","volume":"19","author":"Zhang X.","year":"2019","journal-title":"Molecular Medicine Reports"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03681-9"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-170995"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01139"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102066"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101268"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03583-4"},{"issue":"3","key":"e_1_2_11_38_1","first-page":"840","article-title":"803Immune\u2010Related Adverse Events Correlate With Improved Outcomes in Patients With Advanced Non\u2010Small Cell Lung Cancer Treated With Combinations of Immune\u2010Checkpoint Inhibitors and Chemotherapy","volume":"9","author":"Shantzer L.","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05260-z"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236096"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2018.06.04"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02063"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020487"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1738798"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx636"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.03.004"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220306"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060806"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv489"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.11.016"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1315488"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123735"},{"issue":"7","key":"e_1_2_11_54_1","first-page":"513","article-title":"Expert Consensus on PD\u2010L1 Expression Testing in Non\u2010Small\u2010Cell Lung Cancer in China","volume":"42","author":"Tumor Pathology Committee of Chinese Anti\u2010Cancer Association","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50079-2"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026745"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1215"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.06.022"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-022-00514-8"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10651-5"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04500-7"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.08.013"},{"key":"e_1_2_11_63_1","first-page":"OL1366","article-title":"Cisplatin Induces Programmed Death\u20101\u2010Ligand 1 (PD\u2010L1) Over\u2010Expression in Hepatoma H22 Cells via Erk\/MAPK Signaling Pathway","volume":"56","author":"Qin X.","year":"2010","journal-title":"Cellular and Molecular Biology (Noisy\u2010le\u2010Grand, France)"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104536"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.11.012"},{"key":"e_1_2_11_66_1","unstructured":"Institute JB \u201cPET Evaluation of Response After 1 Course of Chemotherapy as Predictor of Treatment Outcome \u201d(2010)."},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020376"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2618"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-019-09985-y"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0852-9"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26243"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72001","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:04:23Z","timestamp":1784196263000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/cam4.72001"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72001","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2025-05-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72001"}}